References
- Hofmarcher T, Lindgren P, Wilking N, et al. The cost of cancer in Europe 2018. Eur J Cancer. 2020 Apr;129:41–49.
- Fasola G, Aita M, Marini L, et al. Drug waste minimisation and cost-containment in medical oncology: two-year results of a feasibility study. BMC Health Serv Res. 2008 Apr 1;8(1):70. doi: 10.1186/1472-6963-8-70
- Fasola G, Aprile G, Marini L, et al. Drug waste minimization as an effective strategy of cost-containment in oncology. BMC Health Serv Res. 2014 Feb 7;14(1):57. doi: 10.1186/1472-6963-14-57
- Bach PB, Conti RM, Muller RJ, et al. Overspending driven by oversized single dose vials of cancer drugs. BMJ. 2016 Feb 29;352:i788. doi: 10.1136/bmj.i788. .
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA A Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
- AIOM (Associazione Italiana di Oncologia Medica): I numeri del cancro in Italia, 2020. Available from: https://www.aiom.it/wp-content/uploads/2020/10/2020_Numeri_Cancro-operatori-web.pdf. Last accessed: 18 May 2023
- Keen JC, Davidson NE. The biology of breast carcinoma. Cancer. 2003;97(S3):825–833. doi: 10.1002/cncr.11126
- Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009;20(7):1071–1082. doi: 10.1007/s10552-009-9331-1
- Mayer M, Hunis A, Oratz R, et al. Living with metastatic breast cancer: a global patient survey. Community Oncol. 2010;7(9):406–412. doi: 10.1016/S1548-5315(11)70415-6
- Linee Guida 2020 AIOM delle Neoplasie della Mammella. Available from: https://www.aiom.it/wp-content/uploads/2020/10/2020_LG_AIOM_NeoplasieMammella.pdf Last accessed: 18 May 2023
- Ibrance. INN-palbociclib. Available from: https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_it.pdf Last accessed: 18 May 2023
- Kisqali. INN-ribociclib. Available from: https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_it.pdf Last accessed: 18 May 2023
- Verzenios. INN-abemaciclib. Available from: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_it.pdf Last accessed: 18 May 2023
- So.Re.Sa. Società Regionale per la Sanità - Farmaci ed Emoderivati. Available from: www.soresa.it/pa/Pagine/Anagrafe/Farmaci-Emoderivati.aspx Last accessed: 18 May 2023
- Prasad V, Massey PR, Fojo T. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol. 2014;32(15):1620–1629. doi: 10.1200/JCO.2013.53.0204
- Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936. doi: 10.1056/NEJMoa1607303
- Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–1748. doi: 10.1056/NEJMoa1609709
- Daughton CG, Ruhoy IS. Lower-dose prescribing: minimizing “side effects” of pharmaceuticals on society and the environment. Sci Total Environ. 2013;443:324–337. doi: 10.1016/j.scitotenv.2012.10.092
- Baird JA, Starner CI, Bowen K, et al. Palbociclib (Ibrance) utilization and costs among 18 million insured Americans: managed care pharmacy opportunities. Poster presented at the Academy of Managed Care Pharmacy (AMCP) 27th Annual Meeting & Expo 2015. Available from: https://pharmacy.primetherapeutics.com/content/dam/corporate/Documents/Newsroom/PrimeInsights/2015/posters/1015-fall-palbociclib.pdf Last accessed: 18 May 2023
- Galactionova K, Loibl S, Salari P, et al. Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial. Front Oncol. 2022;12:886831. doi: 10.3389/fonc.2022.886831
- Li N, Du EX, Chu L, et al. Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2- metastatic breast cancer. Expert Opin Pharmacother. 2017;18(12):1167–1178. doi: 10.1080/14656566.2017.1351947
- Nota 51. Farmaco in nota: Ulipristal acetato, Triptorelina, Leuprorelina, Goserelina, Buserelina. Available from: https://www.aifa.gov.it/en/nota-51 Last accessed: 18 May 2023
- Moran JL, Solomon PJ, Peisach AR, et al. New models for old questions: generalized linear models for cost prediction. J Eval Clin Pract. 2007 Jun;13(3):381–389. doi: 10.1111/j.1365-2753.2006.00711.x
- Burne R, Balu S, Guérin A, et al. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors. J Med Econ. 2021;24(1):806–815. doi: 10.1080/13696998.2021.1939705
- Patt D, Mitra D, Harrell R, et al. Early treatment utilization of palbociclib for metastatic breast cancer (mBC) in a U.S. community oncology network [abstract. J Clin Oncol. 2016;34(15 Suppl):e18112. Available from: https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.e18112
- Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35. doi: 10.1016/S1470-2045(14)71159-3
- Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–439. doi: 10.1016/S1470-2045(15)00613-0
- Piccinni C, Dondi L, Ronconi G, et al. HR+/HER2- metastatic breast cancer: epidemiology, prescription patterns, healthcare resource utilisation and costs from a large Italian real-world database. Clin Drug Investig. 2019 Oct;39(10):945–951.
- Biskupiak J, Oderda G, Brixner D, et al. Quantification of economic impact of drug wastage in oral oncology medications: comparison of 3 methods using palbociclib and ribociclib in advanced or metastatic breast cancer. J Manag Care Spec Pharm. 2019;25(8):859–866. doi: 10.18553/jmcp.2019.25.8.859
- Zhu L, Wang M, Luo X, et al. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review. Ann Transl Med. 2022 Feb;10(4):233. doi: 10.21037/atm-21-5110